Scand J Urol:前列腺癌术后的融合靶向活检Gleason评分变化

2021-01-09 AlexYang MedSci原创

最近,有研究人员评估了基于MRI/超声融合的靶向活检(FBx)与前列腺切除样本相比,是否会导致Gleason评分(GS)变化率降低。

最近,有研究人员评估了基于MRI/超声融合的靶向活检(FBx)与前列腺切除样本相比,是否会导致Gleason评分(GS)变化率降低

研究人员对2012年至2017年的210名患者的前列腺活检和前列腺根治术(RP)样本的组织病理学结果进行了回顾性比较,并将105名接受FBx联合超声引导下前列腺12核活检术(SBx)的患者与105名仅接受SBx的患者进行了配对。结果表明,在SBx的52/105名患者(49.5%)和FBx的49/105名患者(46.7%)中发现格里森等级组(GGG)是一致的(P=0.679)。降级率有统计学意义(p=0.014),且FBx组(14/105患者,13.3%)高于SBx组(4/105患者,3.8%)。与FBx(42/105患者,40%)相比,SBx(49/105患者;46.7%)的升级率更高,但无统计学显著意义(p=0.331)。GGG1和2级患者的GGG变化从活检到最终病理没有统计学显著性(p=0.168)。

GGG1和GGG2的FBx和SBx的升级和降级率

最后,研究人员指出,FBx不会降低RP样本从活检到最终病理之间的升级率。他们的结果表明,与SBx相比,FBx倾向于高估最终的GGG

原始出处:

M Apfelbeck, S Tritschler , D-A Clevert et al. Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis. Scand J Urol. Dec 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-07-28 huangdf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-11 smlt2008
  4. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-11 licz0427
  5. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-10 oo902

    啥意思,没明白

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-09 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1913770, encodeId=267b1913e701f, content=<a href='/topic/show?id=6f5328e398' target=_blank style='color:#2F92EE;'>#ASO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2873, encryptionId=6f5328e398, topicName=ASO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2e0330, createdName=huangdf, createdTime=Wed Jul 28 16:39:04 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663211, encodeId=97671663211d4, content=<a href='/topic/show?id=8dd2805674' target=_blank style='color:#2F92EE;'>#Gleason评分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8056, encryptionId=8dd2805674, topicName=Gleason评分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=edcf25571494, createdName=ms7517674339485982, createdTime=Fri Aug 27 14:39:04 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278216, encodeId=dd2012e8216bc, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525564, encodeId=bdd0152556429, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88858, encryptionId=08548885835, topicName=融合)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a911636812, createdName=licz0427, createdTime=Mon Jan 11 05:39:04 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915337, encodeId=d02291533e43, content=啥意思,没明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jan 10 19:07:48 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040924, encodeId=1a20104092443, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jan 09 17:39:04 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914910, encodeId=aa8591491090, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sat Jan 09 15:13:36 CST 2021, time=2021-01-09, status=1, ipAttribution=)]
    2021-01-09 jyzxjiangqin

    好文章!

    0

相关资讯

J Rheumatol:系统性硬化症中手指溃疡临床评估评分的初步验证

该研究初步建议DUCAS作为SSc相关性DU的新临床评分,DUCAS具有表面和内容的有效性以及聚合/发散相关性(结构有效性)。

Ann Rheum Dis:巨细胞动脉炎的一种新型超声光晕评分

超声光晕评分可以量化GCA的血管炎症程度。超声上广泛的血管炎症可以强有力的确认GCA诊断,并与眼部缺血相关。

Eur J Nucl Med Mol Imaging:诊断恶性胸腔积液的PET-CT评分

近日,首都医科大学附属北京朝阳医院施焕中教授团队在《European Journal of Nuclear Medicine and Molecular Imaging》上发表题为"Development and validation of the PET-CT score for diagnosis of malignant pleural effusion"的论文。研究团队经过临床研究,提出诊

Sci Rep:系统性红斑狼疮的胃肠道受累

基于CT的评分系统有助于更准确地评估和个性化治疗GI受累的SLE患者。

J Rheumatol:银屑病关节炎中初步超声附着点炎评分的建立-GRAPPA超声工作组

这项研究确定了可以区分PsA和对照的潜在基本超声异常和附着点位点。

膝关节AKS评分

膝关节AKS评分